Group 1 - Bayer's oral anticoagulant Asundexian achieved a 26% reduction in the risk of recurrent non-cardioembolic ischemic stroke in the OCEANIC-STROKE Phase 3 trial, without increasing the risk of major bleeding. The company plans to submit a New Drug Application to the FDA by the end of 2026, positioning Asundexian as a potential blockbuster product [1] - The U.S. EPA approved the federal registration of the low-volatility herbicide Stryax, which Bayer plans to launch in the 2026 planting season to address herbicide-resistant weed issues, subject to strict application restrictions [1] - Bayer's crop science division is responding to China's 2026 Central No. 1 Document by promoting high-yield corn varieties through local R&D, contributing to the development of new agricultural productivity [1] Group 2 - Bayer aims to save €2 billion annually starting in 2026 through its DSO operational model and plans to divest non-core assets, such as the moxifloxacin business, to focus on its innovative drug pipeline [1] - Bayer's original drugs, including acarbose, won bids in the national drug procurement process, covering treatment areas such as diabetes [1] - Bayer's stock price showed slight fluctuations, closing at $13.50 on February 12, with a year-to-date increase of 24.77%, indicating a generally positive long-term sentiment [2] Group 3 - Key drivers for Bayer in 2026 include the approval progress of innovative drugs like Asundexian, cost-saving initiatives, and improved profitability in crop science, although challenges such as patent cliffs and litigation risks may hinder growth [3] - Institutions like WuXi AppTec highlighted the positive Phase 3 data for Asundexian, suggesting it could transform the secondary prevention market for strokes [3]